bioAffinity Technologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIAF and other ETFs, options, and stocks.

About BIAF

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. 

CEO
Maria Zannes
CEOMaria Zannes
Employees
57
Employees57
Headquarters
San Antonio, Texas
HeadquartersSan Antonio, Texas
Founded
2014
Founded2014
Employees
57
Employees57

BIAF Key Statistics

Market cap
3.08M
Market cap3.08M
Price-Earnings ratio
-0.07
Price-Earnings ratio-0.07
Dividend yield
Dividend yield
Average volume
330.96K
Average volume330.96K
High today
$0.52
High today$0.52
Low today
$0.49
Low today$0.49
Open price
$0.50
Open price$0.50
Volume
531.30K
Volume531.30K
52 Week high
$13.50
52 Week high$13.50
52 Week low
$0.49
52 Week low$0.49

Stock Snapshot

bioAffinity Technologies(BIAF) stock is priced at $0.49, giving the company a market capitalization of 3.08M. It carries a P/E multiple of -0.07.

During the trading session on 2026-08-11, bioAffinity Technologies(BIAF) shares reached a daily high of $0.52 and a low of $0.49. At a current price of $0.49, the stock is 0.0% higher than the low and still -5.8% under the high.

Trading volume for bioAffinity Technologies(BIAF) stock has reached 531.3K, versus its average volume of 330.96K.

Over the past 52 weeks, bioAffinity Technologies(BIAF) stock has traded between a high of $13.50 and a low of $0.49.

Over the past 52 weeks, bioAffinity Technologies(BIAF) stock has traded between a high of $13.50 and a low of $0.49.

BIAF News

Investing.com 4d
bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates - Investing.com

...

bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates - Investing.com
TipRanks 4d
BioAffinity Technologies reports Q2 EPS (64c) vs ($5.07) last year

Reports Q2 revenue $1.5M vs $1.27M last year. “Our commercial strategy continues to gain significant traction as physicians increasingly recognize the clinical...

People also own

Based on the portfolios of people who own BIAF. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.